Friday, 16 October 2026European Markets

ATOS Stock Over 14% Down So Far Today

Loading stream...

atos, a france-based digital transformation solutions provider, experienced a dramatic 14.97% drop to eur7.72 last wednesday amidst an overall downward trend in cac 40 which also dropped 1.58% to eur7,28.73. given atos's declining trend over recent sessions and cac 40's performance overall, atos's share market performance appears in sync with overall market conditions impacting it.

the volatility of atos's stock prices

this noteworthy decrease underlines atos's stock prices' volatility. over the last week, month, and quarter, intraday variation averaged 12.96%; negatively for month; negatively for quarter; positive 2.43% respectively indicating significant fluctuations in their share values. furthermore, today saw 439.92% more atos shares traded than its usual amount on the stock exchange, suggesting increased trading activity on their behalf.

a concerning profitability at atos

profitability at atos remains concerning with a trailing twelve-month earnings per share (eps) figure of eur-9.13. this negative eps may be impacting investor trust in atos and contributing to its devaluation; trends within atos's shares underscore the significance of financial literacy when understanding factors affecting stock prices as well as any associated risks involved with investing in them.

the need for investors to stay informed

investors need to remain up-to-date on financial trends and track their portfolio's performance closely so they can anticipate potential market downturns and adapt their investments accordingly.

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com